<?xml version="1.0" encoding="UTF-8"?>
<p id="par0025">Since children remain relatively unaffected by COVID19 disease, it is important to accrue substantial safety data among adults before initiating paediatrics studies, and to further understand the biology of the Kawasaki syndrome to inform the risk-benefit relationship for vaccination of children. In addition, efficacy trials in adults with disease endpoints would be important to provide certainty that new vaccines do not induce enhanced disease, when vaccinees are exposed virus in the community, as has been described in some animal models with previous coronavirus vaccines.</p>
